PMID- 27991929
OWN - NLM
STAT- MEDLINE
DCOM- 20171011
LR  - 20181113
IS  - 1476-5594 (Electronic)
IS  - 0950-9232 (Linking)
VI  - 36
IP  - 23
DP  - 2017 Jun 8
TI  - miR-19a promotes colitis-associated colorectal cancer by regulating tumor 
      necrosis factor alpha-induced protein 3-NF-kappaB feedback loops.
PG  - 3240-3251
LID - 10.1038/onc.2016.468 [doi]
AB  - Chronic inflammation is believed to have a crucial role in colon cancer 
      development. MicroRNA (miRNA) deregulation is common in human colorectal cancers, 
      but little is known regarding whether miRNA drives tumor progression by 
      regulating inflammation. Here, we showed that miR-19a can promote colitis and 
      colitis-associated colon cancer (CAC) development using a CAC mouse model and an 
      acute colitis mouse model. Tumor necrosis factor-alpha (TNF-alpha) stimulation can 
      increase miR-19a expression, and upregulated miR-19a can in turn activate nuclear 
      factor (NF)-kappaB signaling and TNF-alpha production by targeting TNF alpha-induced 
      protein 3 (TNFAIP3). miR-19a inhibition can also alleviate CAC in vivo. Moreover, 
      the regulatory effects of miR-19a on TNFAIP3 and NF-kappaB signaling were confirmed 
      using tumor samples from patients with colon cancer. These new findings 
      demonstrate that miR-19a has a direct role in upregulating NF-kappaB signaling and 
      that miR-19a has roles in inflammation and CAC.
FAU - Wang, T
AU  - Wang T
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing, China.
AD  - Jiangsu Key Laboratory of Molecular Medicine, Nanjing, China.
AD  - Department of Molecular and Cellular Oncology, The University of Texas, MD 
      Anderson Cancer Center, Houston, TX, USA.
FAU - Xu, X
AU  - Xu X
AD  - General Surgery, Jinling Hospital, Medical School, Nanjing University, Nanjing, 
      China.
FAU - Xu, Q
AU  - Xu Q
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing, China.
FAU - Ren, J
AU  - Ren J
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing, China.
FAU - Shen, S
AU  - Shen S
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing, China.
AD  - Jiangsu Key Laboratory of Molecular Medicine, Nanjing, China.
FAU - Fan, C
AU  - Fan C
AD  - General Surgery, Jinling Hospital, Medical School, Nanjing University, Nanjing, 
      China.
FAU - Hou, Y
AU  - Hou Y
AD  - The State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, 
      Medical School, Nanjing University, Nanjing, China.
AD  - Jiangsu Key Laboratory of Molecular Medicine, Nanjing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20161219
PL  - England
TA  - Oncogene
JT  - Oncogene
JID - 8711562
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN19 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (NF-kappa B)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - EC 3.4.19.12 (Tumor Necrosis Factor alpha-Induced Protein 3)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Cell Proliferation
MH  - Colitis/chemically induced/*complications
MH  - Colorectal Neoplasms/etiology/metabolism/*pathology
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - MicroRNAs/genetics/*metabolism
MH  - Middle Aged
MH  - NF-kappa B/genetics/*metabolism
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Signal Transduction
MH  - Tumor Cells, Cultured
MH  - Tumor Necrosis Factor alpha-Induced Protein 3/genetics/*metabolism
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2016/12/20 06:00
MHDA- 2017/10/12 06:00
CRDT- 2016/12/20 06:00
PHST- 2016/06/12 00:00 [received]
PHST- 2016/11/06 00:00 [revised]
PHST- 2016/11/07 00:00 [accepted]
PHST- 2016/12/20 06:00 [pubmed]
PHST- 2017/10/12 06:00 [medline]
PHST- 2016/12/20 06:00 [entrez]
AID - onc2016468 [pii]
AID - 10.1038/onc.2016.468 [doi]
PST - ppublish
SO  - Oncogene. 2017 Jun 8;36(23):3240-3251. doi: 10.1038/onc.2016.468. Epub 2016 Dec 
      19.